New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MyHand-SCI: an Active Hand Orthosis for Spinal Cord Injury
Recruiting
The purpose of this study is to develop and test the hardware and software components of the MyHand-SCI device to assist with hand function for individuals with C6-C7 spinal cord injury.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Spinal Cord Injuries, Tetraplegia
CureDRPLA Global Patient Registry
Recruiting
The objective of the CureDRPLA Global Patient Registry is to establish a longitudinal database of patient-reported data on individuals affected with Dentatorubral-pallidoluysian atrophy (DRPLA) from anywhere in the world. The CureDRPLA Global Patient Registry will address patient needs by: * Expanding patient engagement by documenting quality of life outcomes. * Providing anonymized data to the DRPLA research community on patient experience with the disease and priorities for treatment. * Conn... Read More
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
02/10/2025
Locations: CureDRPLA, New York, New York
Conditions: DRPLA
Incorporating Acupuncture Into ERAS for Ambulatory Total Hip Replacement (THR) Surgery
Recruiting
At this time, no formal ERAS (enhanced recovery after surgery) protocol exists for THR that incorporates perioperative acupuncture. Developing, and more importantly, validating a preliminary fast-track protocol for THR can have a significant impact on reducing recovery time and improving the rate at which this subgroup of surgeries is done on an outpatient basis. Furthermore, previous studies of acupuncture as an adjunctive therapy for postoperative analgesia have primarily investigated patient... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/10/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Acupuncture, Hip Surgery, Opioid Use
Vascular Endothelial Dysfunction in Sleep Apnea
Recruiting
This double-blind placebo-controlled parallel group randomized study design will be used to test whether 4 weeks of atorvastatin 10 mg daily reduces levels of inflammatory markers in OSA patients treated with CPAP (standard of care). The purpose of this study is to investigate: 1) whether statins reduce endothelial inflammation and pro-thrombotic conditions in OSA, including in patients adherent to CPAP (Aim 1); and 2) whether statins reduce endothelial inflammation and pro-thrombotic conditions... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Obstructive Sleep Apnea of Adult
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Recruiting
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 in patients with advanced hematological and solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: North Shore Hematology Oncology Associates, East Setauket, New York
Conditions: Advanced Solid Tumor, Advanced Lymphoma
A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's
Recruiting
The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use. Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Foot Associates of New York, New York, New York
Conditions: Diabetic Foot Ulcer
Abatacept for the Treatment of Giant Cell Arteritis
Recruiting
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to screening will be randomized at a 1:1 ratio to receive subcutaneous abatacept 125mg/week or placebo. Patients who achieve remission will remain on their blinded assignment for 12 months at which time abatacept/placebo will be stopped. Patients who do not achieve remission... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
02/10/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Giant Cell Arteritis
Diffusion MRI for Head and Neck Cancer
Recruiting
The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response. dMRI is a powerful tool to probe treatment-induced change in tumors. It is a unique in vivo imaging technique sensitive to cellular microstructures at the scale of water diffusion length on the order of a few microns. Previous studies have shown that both diffusion coefficient D and diffusional kurtosis coefficient K are promisin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: NYU Langone, New York, New York
Conditions: Head Cancer Neck
Longitudinal Evaluation of Hip Cartilage Degeneration: FAI
Recruiting
Femoroacetabular impingement (FAI) is one of the most common mechanisms leading to the development of early cartilage and labral damage in the non-dysplastic hip. Anatomic abnormalities of the proximal femur and/or acetabulum result in repetitive injury during dynamic hip motion, leading to abnormal regional loading of the femoral head-neck junction against the acetabular rim. The resulting damage to the cartilage, labrum, and surrounding capsular structures predispose the patient to developing... Read More
Gender:
ALL
Ages:
Between 10 years and 35 years
Trial Updated:
02/10/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Femoroacetabular Impingement
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
Recruiting
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF) severity categories based on the American Society of Echocardiography's (ASE) 4-category scale. The software analyzes continuous ECG waveform data acquired by the FDA-cleared Peerbridge COR® ECG Wearable Monitor, an ambulatory patch device designed for use during daily act... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Mount Sinai Hospital, New York, New York
Conditions: Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure with Reduced Ejection Fraction, HFpEF - Heart Failure with Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Recruiting
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2025
Locations: Montefiore Einstein Comprehensive Cancer Center, Bronx, New York
Conditions: Higher-risk Myelodysplastic Syndromes
Noninvasive Vagal Nerve Stimulation
Recruiting
Growing evidence suggests that vagal nerve stimulation (VNS) may be novel and effective in the management of the symptom burden of multiple sclerosis (MS) potentially by reducing inflammation and emotional distress, therefore improving overall well-being. We will complete a pilot study comparing transcutaneous auricular vagus nerve stimulation (taVNS) and transcutaneous cervical vagus nerve stimulation (tcVNS) to a standard intervention of dorsolateral prefrontal cortex (DLPFC) transcranial dir... Read More
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
02/07/2025
Locations: NYU Langone Health, New York, New York
Conditions: Multiple Sclerosis